Merck KGaA Acquires Bio-Techne for $11.3 Billion

Merck KGaA entered a merger agreement on June 25, 2026, to acquire Bio-Techne Corporation (TECH) in a deal valued at $11.3 billion. Deal Structure: Bio-Techne shareholders will receive $73 per share in cash, representing a premium of 23.98% over the stock’s last close. Company Profile: Bio-Techne is a U.S.-based life sciences company that develops and